Treasury / DEA Cannabis Schedule III Rescheduling Pending — Marketing Implications
Marketing that mentions cannabis rescheduling must accurately state the current federal status and Section 280E applicability and must not present proposed rescheduling as final, as federal legalization, or as a certain investment catalyst.
DEA NPRM, Schedules of Controlled Substances: Rescheduling of Marijuana, 89 FR 44597 (May 21, 2024) (FR Doc. 2024-11137); 21 U.S.C. 812(b)(3), (c) Schedule I(c)(10); 26 U.S.C. 280E; 12 U.S.C. 5536(a)(1)(B); 15 U.S.C. 45(a)(1); DEA notices of Apr. 28, 2026 (FR Doc. 2026-08177, new hearing; 2026-08178, prior notice withdrawn); final rule FR Doc. 2026-08176 (FDA-approved marijuana products to Schedule III)